Arcelix
Shionogi to acquire IntraBio in deal worth $2bn
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
Legend Biotech appoints new group of scientific advisors
The company is focused on CAR-T cell therapy to treat multiple myeloma
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression